Jin Medical International Ltd. financials

ZJYL CIK 0001837821

Source: EDGAR filings · Built 2026-06-19T01:48:42Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2023FY 2023
Free Cash Flow -3.73M -1.35M 2.99M 1.54M 5.80M
EBITDA 851.59K 3.88M 3.09M 2.49M 2.98M
Working Capital 20.35M 25.66M 22.19M 13.20M
Net Debt 11.45M 3.47M -2.82M
Gross Margin 29.22% 40.43% 34.23% 32.30% 30.64%
Operating Margin 2.94% 15.48% 14.47% 11.10% 12.67%
Net Margin 5.76% 15.64% 14.52% 14.10% 12.67%
Return on Equity (ROE) 4.02% 12.76% 12.00% 17.76% 18.76%
Return on Assets (ROA) 2.23% 8.03% 8.75% 12.93%
Current Ratio 1.86× 2.50× 3.49× 3.31×
Debt-to-Equity 0.64× 0.40× 0.17×
Effective Tax Rate 13.45% 18.26% 10.67% 1.32% 8.63%
Cash Conversion Ratio 2.44× -0.33× 1.08× 0.58× 2.22×
Accruals Ratio -0.03× 0.11× -0.01× 0.05×
CapEx Coverage 0.44× -8.33× 27.26× 39.35× 136.27×
Free Cash Flow Per Share $-0.02 $-0.01 $0.02 $0.01 $0.04

Income Statement

Concept FY 2025FY 2024FY 2023FY 2023FY 2023
Revenues 20.69M 23.50M 19.82M 19.19M 20.76M
Cost of Goods and Services Sold 14.44M 13.89M 12.86M 12.83M
Cost of Revenue 14.64M 14.00M 13.04M 12.99M 14.40M
Gross Profit 6.04M 9.50M 6.78M 6.20M 6.36M
Research and Development Expense 1.56M 1.50M 1.54M 1.89M 1.57M
Operating Expenses 5.44M 5.86M 3.92M 4.07M 3.73M
Operating Income (Loss) 608.18K 3.64M 2.87M 2.13M 2.63M
Income Tax Expense (Benefit) 214.57K 763.88K 343.71K 36.11K 248.64K
Net Income (Loss) Attributable to Parent 1.19M 3.68M 2.88M 2.71M 2.63M
Earnings Per Share, Basic $0.01 $0.02 $0.02 $0.02 $0.02
Weighted Average Number of Shares Outstanding, Basic 156.55M 156.47M 145.14M 135.00M 135.00M
Earnings Per Share, Diluted $0.01 $0.02 $0.02 $0.02 $0.02
Weighted Average Number of Shares Outstanding, Diluted 156.55M 156.47M 145.14M 135.00M 135.00M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2023FY 2023
Assets, Current 44.14M 42.82M 31.12M 18.90M
Assets 53.37M 45.80M 32.90M 20.94M
Liabilities, Current 23.80M 17.15M 8.92M 5.70M
Liabilities 23.80M 17.25M 8.92M 5.70M
Stockholders' Equity Attributable to Parent 29.64M 28.82M 23.98M 15.24M
Common Stock, Shares, Outstanding 156.55M 155.95M 155.95M 135.00M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2023FY 2023
Net Cash Provided by (Used in) Operating Activities 2.90M -1.21M 3.11M 1.58M 5.84M
Payments to Acquire Property, Plant, and Equipment 6.63M 144.95K 113.94K 40.17K 42.88K
Net Cash Provided by (Used in) Investing Activities -10.79M -9.51M -7.73M -120.90K -1.07M
Net Cash Provided by (Used in) Financing Activities 7.35M 11.65M 6.91M 121.86K -2.87M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ZJYL CIK 0001837821), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

OPTX

SYNTEC OPTICS HOLDINGS, INC.

ZYME

ZYMEWORKS INC.

FIEE

FiEE, Inc.